Janux therapeutics reports second quarter 2025 financial results and business highlights

San diego--(business wire)---- $janx--janux therapeutics, inc. (nasdaq: janx) (janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its tumor activated t cell engager (tractr), tumor activated immunomodulator (tracir), and adaptive immune response modulator (arm) platforms, today reported financial results for the second quarter ended june 30, 2025, and provided a business update. “the recent expansion of our t.
JANX Ratings Summary
JANX Quant Ranking